Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma

BACKGROUND: Adjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in CheckMate-915 did not result in increased RFS. A pilot...

Descripción completa

Detalles Bibliográficos
Autores principales: Khushalani, Nikhil I, Vassallo, Melinda, Goldberg, Judith D, Eroglu, Zeynep, Kim, Younchul, Cao, Biwei, Ferguson, Robert, Monson, Kelsey R, Kirchhoff, Tomas, Amato, Carol M, Burke, Paulo, Strange, Ann, Monk, Emily, Gibney, Geoffrey Thomas, Kudchadkar, Ragini, Markowitz, Joseph, Brohl, Andrew S, Pavlick, Anna, Richards, Alison, Woods, David M, Weber, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717375/
https://www.ncbi.nlm.nih.gov/pubmed/36450385
http://dx.doi.org/10.1136/jitc-2022-005684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717375/
https://www.ncbi.nlm.nih.gov/pubmed/36450385
http://dx.doi.org/10.1136/jitc-2022-005684

Ejemplares similares